A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloroacetate (DCA) in Patients With Newly Diagnosed Glioblastoma Multiform Tumours

AHS Cancer Control Alberta0 sitesJuly 2008

ConditionsGlioblastoma

DrugsDichloroacetate (DCA)

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Glioblastoma
Sponsor: AHS Cancer Control Alberta
Primary Endpoint: Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients.
Status: Withdrawn
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This is a study to see whether radiotherapy plus chemotherapy (Temozolomide) plus Dichloroacetate (DCA) improves overall survival and offers better control of the disease in patients with newly diagnosed Glioblastoma Multiforme Tumours.

Detailed Description

Patients with newly diagnosed Glioblastoma Multiforme Tumours, once consented to the study, would undergo standard treatment of radiotherapy plus chemotherapy (TMZ) with DCA in pill form (twice a day) during the radiation phase of the study and then with TMZ for six months after. Other elements of the clinical trial include pharmacokinetics and MGMT genetic testing.

Registry

clinicaltrials.gov

Start Date

July 2008

End Date

January 2010

Last Updated

10 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

AHS Cancer Control Alberta

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•newly diagnosed GBM
•Diagnosis must be established by open biopsy or tumour resection
•Tumour must have a supratentorial component
•Over 18 years
•pre-treatment evaluations must be met
•study therapy to begin within 6 weeks of surgery
•KPS greater or equal to 70
•patients must sign informed consent
•If female, patients must not be pregnant or lactating
•Women of childbearing potential and male participants must practice adequate contraception

Exclusion Criteria

•prior invasive malignancy )except for non-melanomatous skin cancer) unless disease free for greater than 3 years
•recurrent or multifocal malignant gliomas
•metastatic disease of leptomeningeal spread
•prior chemo or radiosensitizers for cancers of the head and neck region
•prior RT to head and neck region except for T1 glottic cancer, resulting in overlap of radiation fields.
•Severe active co-morbidity define in protocol
•Pregnant of lactating women
•Women of childbearing potential or men who are sexually active who are not willing or able to use medically acceptable forms of contraception; this exclusion is necessary due to the treatment involved potentially being teratogenic.
•prior allergic reaction to temozolomide and/or dichloroacetate
•History of HIV/AIDS

Outcomes

Primary Outcomes

Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients.

Time Frame: 2 years

Secondary Outcomes

To determine if there is a correlation between MGMT promoter methylation status and progression-free survival for newly diagnosed GBM patients undergoing concurrent TMZ, DCA and RT followed by six monthly cycles of TMZ and DCA(2 years)